Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silymarin prevention of ribociclib-related hepatotoxicity in HR-positive/HER2-negative breast cancer
2025-521651-22-00Phase 2Authorised
- Sponsor
- Fondazione Oncotech
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of silymarin and ribociclib in breast cancer, sponsored by Fondazione Oncotech. Primary endpoint: Incidence of grade 2 or higher AST/ALT increase. Planned start Feb 2026; status: authorised.
02
Drugs
silymarinribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2025-521651-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521651-22-00.